首发精神病初始抗精神病药治疗反应与前扣带回谷氨酸水平相关:多中心1H-MRS研究(OPTiMiSE)
该多中心1H-MRS研究在71例未用药或极少用药的首发精神病患者和60名健康志愿者中测量前扣带回和丘脑的谷氨酸水平(Glu/Cr),患者接受氨磺必利治疗4周。结果显示前扣带回Glu/Cr较高与基线症状更重及4周未缓解可能性更低相关(P < 0.05),治疗期间前扣带回和丘脑Glu/Cr均下降(P < 0.05)但与治疗反应无关,患者与对照基线Glu/Cr无差异。
要点
- 前扣带回Glu/Cr较高与首发精神病基线症状更重相关。
- 前扣带回Glu/Cr较高与氨磺必利治疗4周未缓解可能性更低相关(P < 0.05)。
- 治疗期间前扣带回和丘脑Glu/Cr下降,但与治疗反应无关。
核心结论
- 前扣带回谷氨酸水平较高与首发精神病患者基线症状更重及4周抗精神病药治疗未缓解可能性更低相关,且该关联在治疗开始前即可见。
研究设计与样本
- 多中心质子磁共振波谱(1H-MRS)研究,在三个站点纳入首发精神病患者(n = 71)和健康志愿者(n = 60)。
- 患者为未用药或极少用药,扫描后接受氨磺必利治疗4周(n = 65),治疗后重复1H-MRS(n = 46)。
- 缓解状态依据阳性和阴性症状量表(PANSS)评分定义。
主要发现
- 前扣带回Glu/Cr较高与基线症状更严重相关。
- 前扣带回Glu/Cr较高与4周时达到缓解的可能性更低相关(P < 0.05)。
- 治疗期间前扣带回和丘脑Glu/Cr均出现纵向下降(P < 0.05),但这些变化与治疗反应无关。
- 患者与健康志愿者之间基线Glu/Cr无差异。
关键数值与推荐
- 缓解状态依据PANSS评分定义。
- 前扣带回Glu/Cr较高与4周未缓解可能性更低相关(P < 0.05)。
- 治疗期间前扣带回和丘脑Glu/Cr下降(P < 0.05),但与治疗反应无关。
临床怎么用
- 前扣带回谷氨酸水平或可作为首发精神病抗精神病药治疗前预测治疗反应的潜在生物标志物。
- 基线前扣带回Glu/Cr较高的患者可能症状更重且4周缓解可能性更低,提示需更密切监测。
- 治疗期间谷氨酸水平下降不反映治疗反应,不宜单独作为疗效监测指标。
局限性
- 部分患者治疗后未重复1H-MRS(n = 46),纵向数据不完整。
- 仅使用氨磺必利4周,结论不能推广至其他抗精神病药或更长疗程。
- Glu/Cr为比值指标,受肌酸水平影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Conventional antipsychotic medication is ineffective in around a third of patients with schizophrenia, and the nature of the therapeutic response is unpredictable. We investigated whether response to antipsychotics is related to brain glutamate levels prior to treatment. Proton magnetic resonance spectroscopy was used to measure glutamate levels (Glu/Cr) in the anterior cingulate cortex (ACC) and in the thalamus in antipsychotic-naive or minimally medicated patients with first episode psychosis (FEP, n = 71) and healthy volunteers (n = 60), at three sites. Following scanning, patients were treated with amisulpride for 4 weeks (n = 65), then 1H-MRS was repeated (n = 46). Remission status was defined in terms of Positive and Negative Syndrome Scale for Schizophrenia (PANSS) scores. Higher levels of Glu/Cr in the ACC were associated with more severe symptoms at presentation and a lower likelihood of being in remission at 4 weeks (P < 0.05). There were longitudinal reductions in Glu/Cr in both the ACC and thalamus over the treatment period (P < 0.05), but these changes were not associated with the therapeutic response. There were no differences in baseline Glu/Cr between patients and controls. These results extend previous evidence linking higher levels of ACC glutamate with a poor antipsychotic response by showing that the association is evident before the initiation of treatment.
引用
- Egerton A, Broberg BV, Van Haren N, et al. Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre 1H-MRS study (OPTiMiSE). Mol Psychiatry. 2018. PMID: 29880882. doi:10.1038/s41380-018-0082-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。